Catalyst Wire Dossier Catalyst Wire Dossier

Anti-tenascin radiolabeled antibody therapy

· Bradmer Pharmaceuticals Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Anti-tenascin radiolabeled antibody therapy, covering 2011-02-10 to 2011-02-10. Get the full timeline:

Most recent: Clinical Trial Update: Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-tenascin Radiolabeled Antibody Therapy [Phase 3]

See pricing